Amandeep Kalra, MD
Neurology · Kansas City, MONPI 1659546240
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,820 of the $15,397 with a category attached, or 76.8%. 10 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 51.4% of the total. Reporting peaked in 2023 at $7,921 and has fallen 98.5% since, to $120 in 2025.
Across 20 payments — averaging $769.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$8K
- Bayer$6K
- Novocure Inc.$407
- Foundation Medicine, Inc.$277
- Zimmer Biomet$236
- AstraZeneca$103
- plus $141 from 4 others
Across 16 payments — averaging $1586.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$17K
- Beigene, Ltd.$8K
What the payments were for
- Consulting fees$11,82077%
- Speaking & faculty fees$2772%
- Travel & lodging$2,28815%
- Food & beverage$1,0127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 3 | $7,921 |
| Bayer | 4 | $6,312 |
| Novocure Inc. | 4 | $407 |
| Foundation Medicine, Inc. | 2 | $277 |
| Zimmer Biomet | 2 | $236 |
| AstraZeneca | 1 | $103 |
| GT Medical Technologies, Inc | 1 | $75 |
| Gilead | 1 | $33 |
| Novartis | 1 | $20 |
| Edwards Lifesciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vitrakvi$6,312
- Optune$268
- Neuro Plating System$236
- FOUNDATIONONE$202
- FOUNDATIONONE HEME$202
- FOUNDATIONONE CDX$202
- FOUNDATIONFOCUS$202
- FOUNDATIONONE LIQUID CDX$202
- OPTUNE LUA (NOVOTTF-200T)$120
- LYNPARZA$103
How this compares
$15,397 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbamazepine ErCarbamazepine | 20 | $2,560 |
| Levetiracetam | 88 | $1,534 |
| Dexamethasone | 35 | $759 |
| Lacosamide | 19 | $523 |
| Pantoprazole Sodium | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kansas City
- Stanley FisherKansas City$155K
- Rola MahmoudKansas City$155K
- Robert ReddigKansas City$129K
- Samuel GoldlustKansas City$124K
- Brooke HeffernanKansas City$27K
- Susan SifersKansas City$25K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.